Calls for a more flexible approach to vaccine funding

NewsGuard 100/100 Score

Governments should take a broader perspective - including quality-of-life impacts - when considering whether to fund vaccines, according to a paper from the University of New South Wales (UNSW).

A national vaccination program would help improve productivity and cut sick leave for parents, as well as protecting others in society from falling ill, while getting the maximum benefits from population vaccination programs. The call for a more holistic assessment in determining cost-effectiveness of vaccines, including factors such as parents needing to take leave because of a sick child, is made in an editorial which has just been published in the prestigious journal Lancet Infectious Diseases.

"The influenza vaccine is currently recommended for those who are 65 years and older and anyone over 50 with a chronic disease - but it could be even more cost-effective in children," said Professor Raina MacIntyre, head of the School of Public Health and Community Medicine at UNSW.

"Children shed viruses for longer and at higher doses than adults do, which is why families with young children are often plagued with illness," explained Professor MacIntyre, who is the senior author of the paper.

The central argument of the editorial is that vaccinations should have different funding criteria to drugs.

"Vaccines have features that require special consideration when assessing their cost-effectiveness," the authors wrote. "These features are related to herd immunity, quality-of-life losses in young children, parental care and work loss, time preference, uncertainty, eradication, macroeconomics, and tiered pricing."

The paper looks at a range of other vaccination programs which could be implemented in developed countries for diseases such as chickenpox, shingles and hepatitis A.

Professor MacIntyre is affiliated with the National Centre for Immunisation Research. The lead author is Dr Philippe Beutels from the University of Antwerp and the co-author is Dr Paul Scuffham from Griffith University.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The path to a better tuberculosis vaccine runs through Montana